NCT01020565View on ClinicalTrials.gov

A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2005

Conditions
Chronic Hepatitis B
Interventions
DRUG

Entecavir

Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01020565 - A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection | Biotech Hunter | Biotech Hunter